VP1 372-380 (HLA-B*07:02) VPQYGYLTL
€105.00*
Description
This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays
TechData
| Sequence: | VPQYGYLTL |
| Delivery: | 3 weeks |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Capsid protein |
| UniProt Id: | A0A1C8Z4Q6 |
| IEDB Id: | 70458 |
| Species: | Adeno-associated virus |
| Allele: | HLA-B*07:02, H2-Ld |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Infectious disease |
| Purity: | 95% HPLC-MS |